X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
VENCLEXTA®/VENCLYXTO® (venetoclax) is a first-in-class medicine that selectively binds and inhibits B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis.
Lead Product(s): Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: Venclexta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Swiss Biotech Day
Not Confirmed
Contact SupplierDetails:
VENCLEXTA®/VENCLYXTO® (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis.
Lead Product(s): Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: Venclyxta
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2021
Swiss Biotech Day
Not Confirmed
Contact SupplierDetails:
Positive opinion based on data from the VIALE-A and M14-358 trials, which evaluated the safety, efficacy and pharmacokinetics of VENCLYXTO in combination with hypomethylating agents in adult patients with AML.
Lead Product(s): Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: Venclyxto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2021
Swiss Biotech Day
Not Confirmed
Contact SupplierDetails:
In the VIALE-A trial, the median overall survival of patients who received VENCLEXTA plus azacitidine was 14.7 months (11.9, 18.7) vs 9.6 months (7.4, 12.7) in patients who received azacitidine in combination with placebo.
Lead Product(s): Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: Venclexta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2020
Swiss Biotech Day
Not Confirmed
Contact SupplierDetails:
Phase 3 VIALE-A study showed a 34 percent reduction in the risk of death in AML patients who were ineligible for intensive chemotherapy treated with venetoclax plus azacitidine compared to azacitidine plus placebo.
Lead Product(s): Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: Venclexta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2020
Swiss Biotech Day
Not Confirmed
Contact SupplierDetails:
The data reinforce the potential of IMGN632 as a new therapy for patients with relapsed/refractory AML and result showed that they manageable safety profile and 38% composite complete remission rate seen in the higher intensity cohorts.
Lead Product(s): IMGN632,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: IMGN632
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2021
Swiss Biotech Day
Not Confirmed
Contact SupplierDetails:
The data demonstrate the promising anti-leukemia activity and manageable safety profile of the IMGN632 triplet in AML, and we are encouraged by its potential in patients with relapsed/refractory AML, where well-tolerated, effective options remain quite limited.
Lead Product(s): IMGN632,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: IMGN632
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2021
Swiss Biotech Day
Not Confirmed
Contact SupplierDetails:
SLS009 (GFH009) is a small molecule, highly selective CDK9 inhibitor, demostrated anti-tumor activity in the study being investigated for the treatment of relapsed/refractory acute myeloid leukemia.
Lead Product(s): SLS009,Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: GFH009
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
SY-1425 (tamibarotene) is a first-in-class selective retinoic acid receptor alpha (RARα) agonist. It is being evaluated in combination with azacitidine for the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression.
Lead Product(s): Tamibarotene,Azacitidine
Therapeutic Area: Oncology Product Name: SY-1425
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
FP-1305 (bexmarilimab) is a first-in-class, humanized monoclonal antibody, which binds to Clever-1, an immunosuppressive receptor found on macrophages. It is being evaluated for the treatment of higher-risk (HR) myelodysplastic syndrome.
Lead Product(s): Bexmarilimab,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: FP-1305
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Details:
IO-202 is a first-in-class antagonist antibody with specific, high affinity binding to LILRB4. It is being evaluated for the treatment of relapsed or refractory chronic myelomonocytic leukemia.
Lead Product(s): IO-202,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: IO-202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details:
CFI-400945 (ocifisertib) is a first-in-class, investigational PLK4 inhibitor. It is being evaluated for the treatment of relapsed/refractory acute myeloid leukemia.
Lead Product(s): CFI-400945,Azacitidine
Therapeutic Area: Oncology Product Name: CFI-400945
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
GS-4721 (magrolimab) is a monoclonal antibody targeting CD47. It is being evaluated in phase 3 clinical trials for the treatment of TP53 mutant acute myeloid leukemia.
Lead Product(s): Magrolimab,Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: GS-4721
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2024
Details:
Xospata (gilteritinib) is a small molecule that inhibits multiple receptor tyrosine kinases, including FLT3. It is being evaluated in combination with venetoclax & azacitidine for the treatment of relapsed/refractory acute myeloid leukaemia with a FLT3 mutation.
Lead Product(s): Gilteritinib Fumarate,Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: Xospata
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Details:
FP-1305 (bexmarilimab) is a monoclonal antibody that binds to Clever-1. It is being evaluated in phase 1/2 clinical trials for the treatment of acute myeloid leukemia, myelodysplastic syndromes & chronic myelomonocytic leukemia.
Lead Product(s): Bexmarilimab,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: FP-1305
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2024
Details:
FP-1305 (bexmarilimab) is a CLEVER-1 binder, which is under phase 1/2 clinical development in combination with azacitidine & venetoclax for the treatment of acute myeloid leukemia, myelodysplastic syndromes & chronic myelomonocytic leukemia.
Lead Product(s): Bexmarilimab,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: FP-1305
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
SP-2577 (Seclidemstat) is an oral LSD1 inhibitor. It is being evaluated in phase 1 /2 clinical trials in combination with Azacitidine for the treatment of Hematologic Cancers.
Lead Product(s): Seclidemstat,Azacitidine
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
The net proceeds will be used to fund the ongoing clinical development of SY-1425 (tamibarotene), a first-in-class selective retinoic acid receptor alpha (RARα) agonist, being developed for myelodysplastic syndromes.
Lead Product(s): Tamibarotene,Azacitidine
Therapeutic Area: Oncology Product Name: SY-1425
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: TD Cowen
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 19, 2023
Details:
SL-172154 (SIRPα-Fc-CD40L) is an investigational ARC fusion protein designed to simultaneously inhibit the CD47/SIRPα checkpoint interaction and activate the CD40 costimulatory receptor to bolster an anti-tumor immune response in patients with advanced cancer.
Lead Product(s): SL-172154,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: SL-172154
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
SNDX-5613 (revumenib) is a highly selective, oral menin inhibitor which is under phase 1 clinical development for the treatment of patients with Acute Leukemias.
Lead Product(s): Revumenib,Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: SNDX-5613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
The collaboration aims to support Mendus to focus on the development of its lead product candidate DCP-001 (vididencel) in combination with oral azacitidine as a potential novel maintenance treatment in acute myeloid leukemia.
Lead Product(s): Vididencel,Azacitidine
Therapeutic Area: Oncology Product Name: DCP-001
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Australasian Leukaemia & Lymphoma Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 06, 2023
Details:
SELECT-AML-1 is evaluating the safety and efficacy of SY-1425 (tamibarotene) in combination with venetoclax and azacitidine compared to venetoclax and azacitidine in patients patients with acute myeloid leukemia and RARA gene overexpression.
Lead Product(s): Tamibarotene,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: SY-1425
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
FP-1305 (bexmarilimab) binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases, which is investigated for the treatment of relapsed/refractory AML and HMA-refractory MmDS patients.
Lead Product(s): Bexmarilimab,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: FP-1305
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
SLS009 (GFH009) is a small molecule, highly selective CDK9 inhibitor, demostrated anti-tumor activity in the study being investigated for the treatment of relapsed/refractory (r/r) acute myeloid leukemia.
Lead Product(s): GFH009,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: SLS009
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Details:
FP-1305 (bexmarilimab) binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases, which is investigated for the treatment of relapsed/refractory AML and HMA-refractory MmDS patients.
Lead Product(s): Bexmarilimab,Azacitidine
Therapeutic Area: Oncology Product Name: FP-1305
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
AK117 (ligufalimab) is a next generation of humanized lgG4 anti-CD47 antibody without hemagglutination effect, which is investigated in Combination with Azacitidine for the treatment of Myelodysplastic Syndromes.
Lead Product(s): Ligufalimab,Azacitidine
Therapeutic Area: Oncology Product Name: AK117
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
GS-4721 (magrolimab), a potential, first-in-class investigational monoclonal antibody that binds to CD47 and block the inhibitory CD47-signal regulatory protein (SIRPα) interaction, is being developed in several hematologic cancers and solid tumor malignancies.
Lead Product(s): Magrolimab,Azacitidine
Therapeutic Area: Oncology Product Name: GS-4721
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
Under the termination, I-Mab will regain the full global rights to develop and commercialize certain CD47 compounds and products under the Collaboration Agreement, including TJC4 (lemzoparlimab), a fully human anti-CD47 IgG4 antibody.
Lead Product(s): Lemzoparlimab,Azacitidine
Therapeutic Area: Oncology Product Name: TJC4
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $1,940.0 million Upfront Cash: $180.0 million
Deal Type: Termination September 22, 2023
Details:
GS-4721 (magrolimab), a potential, first-in-class investigational monoclonal antibody that binds to CD47 and block the inhibitory CD47-signal regulatory protein (SIRPα) interaction, is being developed in several hematologic cancers and solid tumor malignancies.
Lead Product(s): Magrolimab,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: GS-4721
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
Details:
ALX148 (evorpacept) is a fusion protein comprised of an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin, being developed for the treatment of myelodysplastic syndromes.
Lead Product(s): Evorpacept,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Details:
GS-4721 (magrolimab), a potential, first-in-class investigational monoclonal antibody that binds to CD47 and block the inhibitory CD47-signal regulatory protein (SIRPα) interaction, is being developed in several hematologic cancers and solid tumor malignancies.
Lead Product(s): Magrolimab,Azacitidine
Therapeutic Area: Oncology Product Name: GS-4721
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2023
Details:
FP-1305 (bexmarilimab) binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system).
Lead Product(s): Bexmarilimab,Azacitidine
Therapeutic Area: Oncology Product Name: FP-1305
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2023
Details:
Curis intends to use the net proceeds from the offering on research and development of CA-4948 (emavusertib), an Oral, small molecule IRAK4 kinase inhibitor, being developed for the treatment of Leukemia.
Lead Product(s): Emavusertib,Azacitidine
Therapeutic Area: Oncology Product Name: CA-4948
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cantor Fitzgerald & Co.
Deal Size: $15.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 06, 2023
Details:
CA-4948 (emavusertib) is a triple target inhibitor (IRAK4, FLT3 and CLK), which is investiated for patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS).
Lead Product(s): Emavusertib,Azacitidine
Therapeutic Area: Oncology Product Name: CA-4948
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2023
Details:
GFH009 is a small molecule, highly selective CDK9 inhibitor, demostrated anti-tumor activity in the study being investigated for the treatment of acute myeloid leukemia (AML).
Lead Product(s): GFH009,Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: GFH009
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
The Company intends to use the net proceeds for further development of its product candidates, including SP 2577 (seclidemstat), a potent and orally bioavailable inhibitor of lysine-specific demethylase 1.
Lead Product(s): Seclidemstat,Azacitidine
Therapeutic Area: Oncology Product Name: SP 2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 16, 2023
Details:
The Company intends to use the net proceeds for further development of its product candidates, including SP 2577 (seclidemstat), a potent and orally bioavailable inhibitor of lysine-specific demethylase 1.
Lead Product(s): Seclidemstat,Azacitidine
Therapeutic Area: Oncology Product Name: SP 2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 12, 2023
Details:
ABBV-IMAB-TJC4 (lemzoparlimab) is a novel CD47 antibody, in combination with azacitidine (AZA), currently being investigated in China for patients with higher-risk myelodysplastic syndrome (MDS).
Lead Product(s): Lemzoparlimab,Azacitidine
Therapeutic Area: Oncology Product Name: ABBV-IMAB-TJC4
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2023
Details:
With the partial hold, FDA is requesting additional data from the study, including data related to the death of R/R AML patient who experienced, among several conditions, rhabdomyolysis, which has previously been identified as a dose-limiting toxicity of CA-4948 (emavusertib).
Lead Product(s): Emavusertib,Azacitidine
Therapeutic Area: Oncology Product Name: CA-4948
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aurigene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
Under the Licensing Agreement, OncoVerity will optimize JNJ-74494550 (cusatuzumab), a first-in-class anti-CD70 antibody, in acute myeloid leukemia (AML) and explore its application in other cancers.
Lead Product(s): Cusatuzumab,Azacitidine
Therapeutic Area: Oncology Product Name: JNJ-74494550
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: OncoVerity
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 27, 2023
Details:
The net proceeds will be used for the continued development JNJ-74494550 (cusatuzumab), a first-in-class anti-CD70 antibody for the treatment of acute myeloid leukemia (AML).
Lead Product(s): Cusatuzumab,Azacitidine
Therapeutic Area: Oncology Product Name: JNJ-74494550
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Argenx
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 27, 2023
Details:
AB8939 is a new synthetic microtubule-destabilizing drug, having broad anticancer activity, with a notable advantage over standard chemotherapies that target microtubules of being able to overcome Pgp and MPO mediated drug resistance.
Lead Product(s): AB8939,Azacitidine
Therapeutic Area: Oncology Product Name: AB8939
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
Rezlidhia (olutasidenib) is a small-molecule inhibitor of mutated isocitrate dehydrogenase-1 (IDH1). It is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptibleisocitrate dehydrogenase-1 (IDH1) mutation.
Lead Product(s): Olutasidenib,Azacitidine
Therapeutic Area: Oncology Product Name: Rezlidhia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
Details:
SY-1425 (tamibarotene), an oral first-inclass selective retinoic acid receptor alpha (RARα) agonist, is currently being evaluated in combination with azacitidine for the treatment of newly diagnosed HR-MDS patients with RARA gene overexpression.
Lead Product(s): Tamibarotene,Azacitidine
Therapeutic Area: Oncology Product Name: SY-1425
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2023
Details:
Rezlidhia (olutasidenib) is a small-molecule inhibitor of mutated isocitrate dehydrogenase-1 (IDH1). It is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptibleisocitrate dehydrogenase-1 (IDH1) mutation.
Lead Product(s): Olutasidenib,Azacitidine
Therapeutic Area: Oncology Product Name: Rezlidhia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
Azacitidine is a pyrimidine nucleoside analog of cytidine. It is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow.
Lead Product(s): Azacitidine
Therapeutic Area: Oncology Product Name: Vidaza-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
Details:
The rates of myelosuppression were comparable to SY-1425 (azacitidine) monotherapy in this population suggesting no added hematologic toxicity from tamibarotene when used in combination with azacitidine. The majority of non-hematologic adverse events (AEs) were low grade.
Lead Product(s): Tamibarotene,Azacitidine
Therapeutic Area: Oncology Product Name: SY-1425
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
APVO436 is a bispecific CD3xCD123 ADAPTIR currently in Phase 1b development in a multi-center, multi-cohort trial designed to evaluate safety, tolerability and efficacy in combination therapy and monotherapy for patients with AML.
Lead Product(s): APVO436,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: APVO436
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
Evorpacept in combination with azacitidine and venetoclax was generally well tolerated (N=14) with no maximum tolerated dose identified and a maximum administered dose of 60 mg/kg Q4W.
Lead Product(s): Evorpacept,Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
SY-1425, having tamibarotene in combination with venetoclax and azacitidine administered at approved doses showed no evidence of increased toxicity relative to the doublet combination of venetoclax and azacitidine.
Lead Product(s): Tamibarotene,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: SY-1425
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
